St. Cloud Surgical Center is First ASC in U.S. to Utilize Xenex Germ-Zapping Robot to Disinfect Operating Rooms & Enhance Patient Safety more

4 cheap small cap stocks I’ve got my eye for Christmas more

Southern Biologics Network Established to Create Biologics Faster and Less Expensively more

Morningside Ministries at the Manor is the First Skilled Nursing Facility in Texas to Protect Residents with Xenex Germ-Zapping Robot more

RBA to cut rates in 2015: Still want to invest in term deposits? more

Can robots help stop the Ebola outbreak? more

Robots Help Fight Ebola more

South Florida Hospital Unveils Ebola-Zapping Robot more

Sonoma Valley Hospital uses robot to kill germs more

Robots go to war against Ebola more

New iTraumaCare CEO to pursue big growth more

UAB and SRI have plans to spinoff more success more

Launch of Galderma's new acne products more

iTraumaCare’s new CEO to help company secure new funding more

U.S. Air Force Hospital Langley Adds Xenex Ebola-Zapping Robot to Inventory more

Forthcoming Acne Treatment Made With Exclusive (And Sustainable) East Indian Sandalwood Oil more

Sonoma Valley Hospital Acquires Xenex Germ-Killing Robot to Enhance Patient Safety more

Robot fights germs at Sharp Chula Vista Medical Center more

Xenex updates protocols for germ-zapping robots in response to Ebola threat more

How do we get rid of the endotoxins? Birmingham's  has the solution more

Medical Device ® Positions New Leader for Next-Level Growth more

The Xenex robot at South Shore Hospital featured on an Xploration Earth more

Germ-zapping robot Gigi sets its sights on Ebola more

Morningside Ventures leads a Series B round for DNAtrix more

StemBioSys secures new research space at BioBridge Global more

Birmingham's Soluble Therapeutics acquires Seattle company Dilyx Biotechnology more

Company invents germ-zapping robot more

Xenex Congratulates Houston Cancer Hospital more

Australian grown Indian Sandalwood timber attracts lucrative Asian markets more

DNATRIX ANNOUNCES TREATMENT OF FIRST PATIENT WITH DNX-2401 more

Targeted Technology raises more than $40 million more

Reducing Healthcare Associated Infections (HAIs): Not All UV Light is the Same more

Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO

SAN ANTONIO, Sept. 2, 2014 /PRNewswire/ -- Bluegrass Vascular Technologies (BVT), a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, has announced the appointment of Dr. Gabriele Niederauer, a seasoned senior medical device executive, to President and CEO. Following the recent closure of Series A financing, BVT is focused on obtaining CE Mark for the Surfacer™ Inside-Out Access Catheter System, a proprietary system that allows physicians to gain venous access using a novel "inside-out" approach.

"Gabriele is a great addition to the team," stated Dr. Paul Castella, Senior Managing Partner of Targeted Technology Funds, a leading investor in BVT.  "She has over 20 years of experience in the development and commercialization of medical devices and is a great fit to lead the company to commercialization in Europe and the US."

Prior to BVT, Dr. Niederauer was Vice President of R&D for ArthoCare Corporation, ENT-Sinus Division, a Smith-Nephew Company, where she was instrumental in developing and commercializing novel implants and instruments for sinus surgery. She also held senior management roles at ENTrigue Surgical, C2M Medical and OsteoBiologics. An experienced early-stage executive and respected leader of innovation, Dr. Niederauer has over 20 peer-reviewed articles, 9 US patents, and has developed and launched dozens of products, including resorbable implants, instruments and fixation devices. 
 
"BVT has developed a critical mission to address shortcomings in the venous access market. I am honored to join the team and build upon that mission to bring superior, life-saving technologies to the market," commented Dr. Niederauer.  "I look forward to working with the team to commercialize the innovative Surfacer System."

Co-founder and former CEO, Jim Clifton, will transition to the role of Chief Operating Officer (COO) where he will be responsible for company operations, project management and market strategy.

About Bluegrass Vascular Technologies: Bluegrass Vascular Technologies is a medical technology company dedicated to developing and commercializing life-saving devices and methods that address shortcomings in vascular access procedures. The company's initial product offering is the Surfacer™ Inside-Out Access Catheter System, a proprietary system that allows physicians to perform a novel "inside-out" approach to gaining venous access. For more information, please visit www.bluegrassvascular.com.

About Targeted Technology: Targeted Technology is a San Antonio-based venture capital firm which focuses on early stage investments in companies that can advance ground breaking or disruptive technologies to significantly improve the practice of medicine and patient outcomes as well as positively improve the efficiency, cost, or functionality of the development and manufacture of life science products. For more information please visit www.targetedtech.com.

SOURCE Bluegrass Vascular Technologies back

Three Birmingham companies recognized in PwC report more

Former Kinetic Concepts Inc. CEO to lead StemBioSys more

International dermatology company Galderma confirmed more

AUSTRALIAN Sandalwood producer TFS Corporation will supply oil more

San Antonio luring biotech firms with venture capital more

Biotech firm secures nearly $5 million in funding, is relocating to San Antonio more

Birmingham is on the front lines of medical research: take a look at this incredible biotech startup more

Germ-Zapping Robots Fight C. diff and MRSA at Mercy Health Saint Mary's more

Milford hospital enlists robots in war against infections more

Xenex Testifies About UV Room Disinfection Technology Effectiveness to U.S. House of Representatives more

Western Pa. hospitals test robot using ultraviolet rays to kill bacteria more

Xenex Demonstrates UV Room Cleaning System’s Effectiveness in Reducing Hospital Acquired Infections more

TFS flags record full-year profit more

Sweet scented sandalwood flavour of month more

House committee looks for new technology in Veterans Affairs hospitals more

FDA grants fast track status to drug DNX-2401 for recurrent Glioblastoma more

CEO shakeup at San Antonio biotech company StemBioSys more

First harvest to be completed in June more

BiO2 Medical Enrolls Subjects in the New U.S. FDA Early Feasibility Pilot Study for the Angel® Catheter more

San Antonio biotech firm readies skin treatment for distribution more

ViroXis Gets Approval To Initiate FDA Phase 2 Study For Molluscum Contagiosum more

Medical technologies conference announces speaker lineup more

Australian sandalwood sells for millions more

Sandalwood exports as good as gold more

Santalis Pharmaceuticals Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize OTC Dermatology Products more

ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product more

DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas more

ViroXis Corporation Achieves Key Clinical Milestones more

There are growing concerns about the threat of an antibiotic crisis caused by the spread of drug-resistant superbugs. Those concerns could result in more